Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02408549) enrolled 239 participants, all of whom received the medication lacosamide. Of those, 157 completed the study and 82 did not. The trial was a long-term follow-on study that focused on monitoring unwanted events (called adverse events) that occurred during treatment, as well as tracking whether participants developed any new types of seizures — specifically absence seizures (brief "blank staring" episodes) or myoclonic seizures (sudden brief muscle jerks) — that they had not experienced before starting the medication. The reported data shows that out of 239 participants, 222 experienced at least one treatment-emergent adverse event (meaning an unwanted event that appeared or got worse after starting the medication). Of these, 19 participants withdrew from the study because of such events. Regarding new seizure types, the reported data shows that 3 participants developed new absence seizures and 5 developed new myoclonic seizures during the treatment period who had not had those seizure types before. The data also tracked whether absence seizures became more frequent compared to a pre-treatment baseline period: 5 participants showed an increase of up to 25% in days with absence seizures per 28 days, 1 participant showed an increase of more than 25% up to 50%, and no participants showed an increase of more than 50% up to 75%. Figures beyond that range were not reported in the submitted data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Epilepsy Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must have either completed the related parent study (NCT02408523) or have been a certain type of participant who did not meet that study's requirements from the start ("Baseline failure").
- In some cases, people who were screened for the parent study but did not fully participate may also be considered, if the study doctor believes you could benefit from the treatment and gets approval from the UCB study team.
Who may not be able to join:
- You are currently taking another experimental drug or using an experimental medical device (other than the study drug, lacosamide).
- You met the reasons for being removed from the parent study, or you are currently experiencing a serious medical side effect that has not resolved.
- You are currently having active thoughts of suicide, as identified by a specific questionnaire used in the study (confirm with trial site).
- Your liver blood test results are significantly above the normal range — specifically, certain liver enzymes or bilirubin levels that are too high may disqualify you, though some borderline results may be re-tested once to confirm (confirm with trial site for exact details).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of Study Participants With Treatment-emergent Adverse Events (TEAEs) Over the Duration of the Treatment Period; Number of Study Participants Withdrawn Due to TEAEs; Number of Study Participants With New Appearance of Absence and/or Myoclonic Seizures During the Treatment Period; Number of Study Participants With an Increase of up to 25% in Days With Absence Seizures Per 28 Days During the Treatment Period as Compared to the Prospective Baseline (of Study SP0982); Number of Study Participants With an Increase of Greater Than (>)25% to 50% in Days With Absence Seizures Per 28 Days During...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.